BMRA: AI 评分 42/100 — AI 分析 (4月 2026)

Biomerica, Inc. develops, manufactures, and markets diagnostic and therapeutic products for various medical conditions. The company focuses on gastrointestinal diseases, food intolerances, diabetes, and COVID-19, serving physicians' offices, drugstores, and laboratories.

Key Facts: Price: $2.06 AI Score: 42/100 Sector: Healthcare

公司概况

概要：

Biomerica, Inc. (BMRA) pioneers diagnostic and therapeutic solutions for gastrointestinal diseases and related conditions, offering a unique portfolio of patented products and a developing InFoods IBS therapy, positioning it for growth in the medical device sector despite current profitability challenges.

BMRA是做什么的？

Biomerica, Inc., founded in 1971 and headquartered in Irvine, California, is a biomedical technology company specializing in the development, patenting, manufacturing, and marketing of diagnostic and therapeutic products. The company's core focus is on creating solutions for the detection and treatment of various medical conditions and diseases worldwide. Biomerica's diagnostic test kits analyze blood, urine, or fecal specimens to diagnose diseases and medical complications by measuring bacteria, hormones, antibodies, and antigens. These tests are crucial for identifying gastrointestinal diseases, food intolerances, diabetes, and other esoteric conditions. Biomerica distributes its products through physicians' offices, over-the-counter drugstores, and hospital/clinical laboratories. A key product in development is InFoods, an irritable bowel syndrome (IBS) therapy technology and diagnostic-guided therapy. The company also offers Helicobacter pylori products and diagnostic products for COVID-19 infection. Biomerica's evolution has been marked by a commitment to innovation in diagnostic and therapeutic solutions, particularly in the gastroenterology space. Despite its long history, the company faces challenges in achieving profitability, as reflected in its current financial metrics.

BMRA的投资论点是什么？

Investing in Biomerica (BMRA) presents a speculative opportunity based on its innovative InFoods IBS therapy and diagnostic products. While the company's current P/E ratio of -1.47 and a negative profit margin of -90.3% indicate financial challenges, the potential for InFoods to gain market traction in the IBS therapy space could be a significant value driver. The company's low Beta of 0.20 suggests lower volatility compared to the market. Key catalysts include successful clinical trial outcomes for InFoods and increased adoption of its diagnostic tests. the may be worth researching risks associated with the company's financial performance and the competitive landscape, but the potential for growth in the diagnostic and therapeutic markets makes BMRA a compelling, albeit high-risk, investment.

BMRA在哪个行业运营？

Biomerica operates in the medical device industry, which is characterized by rapid innovation and stringent regulatory requirements. The market for diagnostic and therapeutic products is driven by increasing healthcare expenditure and a growing prevalence of chronic diseases such as gastrointestinal disorders and diabetes. The competitive landscape includes companies like ALZN, CELZ, HSCS, IINN, and LFWD, as well as larger players with established market positions. Biomerica's focus on specialized diagnostic and therapeutic solutions, particularly in gastroenterology, allows it to carve out a niche in this competitive environment. The global medical devices market is projected to reach trillions of dollars in the coming years, offering substantial growth opportunities for companies with innovative and effective products.

Medical - Devices

Healthcare

BMRA有哪些增长机遇？

InFoods IBS Therapy: The development and commercialization of InFoods, a diagnostic-guided therapy for Irritable Bowel Syndrome (IBS), represents a significant growth opportunity. The IBS market is estimated to be worth billions of dollars, and a successful therapy could capture a substantial share. Timeline: Clinical trials and regulatory approvals are ongoing, with potential market entry within the next 2-3 years. Competitive Advantage: A personalized, diagnostic-driven approach to IBS treatment.
Expansion of COVID-19 Diagnostic Products: Continued sales and development of diagnostic products for COVID-19 infection can provide revenue growth, especially with potential future waves or variants. The global market for COVID-19 diagnostics remains significant. Timeline: Ongoing, with potential for new product iterations and increased market penetration in the next year. Competitive Advantage: Established diagnostic product line and distribution network.
Gastrointestinal Disease Diagnostics: Increasing the market penetration of existing diagnostic test kits for gastrointestinal diseases, such as H. pylori and food intolerances, represents a steady growth opportunity. The market for GI diagnostics is expanding due to increased awareness and diagnosis rates. Timeline: Ongoing, with continuous marketing and sales efforts. Competitive Advantage: Patented technologies and established relationships with physicians' offices and laboratories.
Diabetes Diagnostic Products: Leveraging existing diagnostic technologies to develop and market new products for diabetes management and monitoring can tap into a large and growing market. The global diabetes diagnostics market is projected to reach billions of dollars. Timeline: Product development and market launch within the next 3-5 years. Competitive Advantage: Expertise in developing and manufacturing diagnostic test kits.
Strategic Partnerships and Acquisitions: Forming strategic alliances with larger healthcare companies or acquiring complementary technologies can accelerate growth and expand market reach. Partnerships can provide access to new markets and distribution channels. Timeline: Ongoing, with potential for deals to be announced in the next 1-2 years. Competitive Advantage: Enhanced market access and product portfolio.

Market Cap of $0.01B indicates a micro-cap stock with potential for high growth but also higher risk.
Negative P/E Ratio of -1.47 reflects current unprofitability, requiring careful monitoring of future earnings.
Gross Margin of 5.6% is significantly lower than industry averages, highlighting the need for improved cost management.
Beta of 0.20 suggests the stock is less volatile than the overall market.
No Dividend Yield indicates that the company is reinvesting earnings for growth, which may appeal to growth-oriented investors.

BMRA提供哪些产品和服务？

Develops diagnostic test kits for analyzing blood, urine, and fecal specimens.
Manufactures and markets diagnostic and therapeutic products.
Focuses on detection and treatment of medical conditions and diseases.
Offers products for gastrointestinal diseases, food intolerances, and diabetes.
Develops InFoods, an irritable bowel syndrome therapy technology.
Sells diagnostic products for COVID-19 infection.
Patents its diagnostic and therapeutic products.

BMRA如何赚钱？

Develops and manufactures diagnostic test kits and therapeutic products.
Sells products to physicians' offices, over-the-counter drugstores, and hospital/clinical laboratories.
Generates revenue through direct sales of diagnostic and therapeutic products.
Focuses on patented and proprietary technologies to maintain competitive advantage.

Physicians' offices
Over-the-counter drugstores
Hospital/clinical laboratories
Patients seeking diagnostic tests and therapies

Patented diagnostic and therapeutic products.
Proprietary InFoods IBS therapy technology.
Established relationships with physicians' offices and laboratories.
Expertise in developing and manufacturing diagnostic test kits.

什么因素可能推动BMRA股价上涨？

Upcoming: Clinical trial results for InFoods IBS therapy.
Upcoming: Regulatory approvals for new diagnostic products.
Ongoing: Increased sales and marketing efforts for existing products.
Ongoing: Strategic partnerships and collaborations.

BMRA的主要风险是什么？

Potential: Failure to obtain regulatory approvals for InFoods or other products.
Potential: Competition from established medical device companies.
Ongoing: Negative profit margins and limited financial resources.
Potential: Product liability claims.
Ongoing: Dependence on key products and markets.

BMRA的核心优势是什么？

Patented diagnostic and therapeutic products.
Proprietary InFoods IBS therapy technology.
Established distribution channels.
Expertise in gastroenterology diagnostics.

BMRA的劣势是什么？

Negative profit margins.
Limited financial resources.
Dependence on key products.
Small market capitalization.

BMRA有哪些机遇？

Expansion of InFoods IBS therapy market.
Increased adoption of COVID-19 diagnostic products.
Strategic partnerships and acquisitions.
Development of new diagnostic products for diabetes and other diseases.

BMRA面临哪些威胁？

Competition from larger medical device companies.
Regulatory hurdles and approval processes.
Economic downturn affecting healthcare spending.
Product liability claims.

BMRA的竞争对手是谁？

Alzamend Neuro, Inc. — Focuses on Alzheimer's disease therapeutics. — (ALZN)
Creative Medical Technology Holdings, Inc. — Develops regenerative medicine therapies. — (CELZ)
HeartSciences — Develops AI-based ECG technology. — (HSCS)
Inno Holdings Inc. — Diversified holding company with healthcare interests. — (IINN)
Life Forward, Corp. — Focuses on health and wellness products. — (LFWD)

Key Metrics

Price: $2.06 (-2.61%)
Market Cap: $7.0M
MoonshotScore: 42/100

常见问题

What does Biomerica, Inc. (BMRA) do?

Biomerica, Inc. (BMRA) is a biomedical technology company that develops, manufactures, and markets diagnostic and therapeutic products. Their primary focus is on creating solutions for detecting and treating various medical conditions, particularly gastrointestinal diseases, food intolerances, and diabetes. BMRA's diagnostic test kits analyze patient samples to identify diseases and measure specific substances in the body. They distribute these products to physicians' offices, drugstores, and laboratories, also developing the InFoods IBS therapy.

Is BMRA stock a good buy?

BMRA stock presents a speculative investment opportunity. While the company's negative P/E ratio and profit margin raise concerns, the potential success of its InFoods IBS therapy and continued demand for its diagnostic products could drive future growth. Investors should weigh the risks associated with its financial performance against the potential for market expansion in the diagnostic and therapeutic sectors. A low Beta of 0.20 suggests lower volatility, but careful consideration of the company's financials is crucial.

What are the main risks for BMRA?

The main risks for BMRA include its current negative profit margins and limited financial resources, which could hinder its ability to fund ongoing operations and product development. Competition from larger, more established medical device companies poses a significant threat. Regulatory hurdles and the need for approvals for new products, particularly InFoods, also present substantial risks. Additionally, potential product liability claims could negatively impact the company's financial stability.

What catalysts could move BMRA stock?

Several catalysts could positively impact BMRA stock. Successful clinical trial results for the InFoods IBS therapy would be a major catalyst, potentially leading to regulatory approval and market adoption. Positive earnings reports showing improved profitability and revenue growth could also drive the stock price higher. Strategic partnerships with larger healthcare companies or acquisitions of complementary technologies could further boost investor confidence and market reach.

What is BMRA stock price target?

As of 2026-03-03, there is no readily available analyst consensus price target for BMRA stock due to its micro-cap status and limited analyst coverage. A fair value estimate would require a detailed financial model, considering factors such as projected revenue growth from InFoods and diagnostic products, cost management improvements, and the overall market conditions for medical devices. Investors should conduct their own due diligence or consult with a financial advisor to determine a suitable valuation.